Phenotype plasticity rather than repopulation from CD90/CK14+ cancer stem cells leads to cisplatin resistance of urothelial carcinoma cell lines by Margaretha A. Skowron et al.
RESEARCH Open Access
Phenotype plasticity rather than
repopulation from CD90/CK14+ cancer
stem cells leads to cisplatin resistance of
urothelial carcinoma cell lines
Margaretha A. Skowron1, Günter Niegisch1*, Gerhard Fritz2, Tanja Arent3, Joep G. H. van Roermund4,
Andrea Romano5, Peter Albers1, Wolfgang A. Schulz1 and Michèle J. Hoffmann1
Abstract
Background: Tumour heterogeneity and resistance to systemic treatment in urothelial carcinoma (UC) may arise
from cancer stem cells (CSC). A recent model describes cellular differentiation states within UC based on
corresponding expression of surface markers (CD) and cytokeratins (CK) with CD90 and CK14 positive cells
representing the least differentiated and most tumourigenic population. Based on the fact that this population is
postulated to constitute CSCs and the origin of cisplatin resistance, we enriched urothelial carcinoma cell lines
(UCCs) for CD90 and studied the tumour-initiating potential of these separated cells in vitro.
Methods: Magnetic- and fluorescence-activated- cell sorting were used for separation of CD90+ and CD90− UCCs.
Distribution of cell surface markers CD90, CD44, and CD49f and cytokeratins CK14, CK5, and CK20 as well as the
effects of short- and long-term treatment with cisplatin were assessed in vitro and measured by qRT-PCR,
immunocytochemistry, reporter assay and flow cytometry in 11 UCCs.
Results: We observed cell populations with surface markers according to those reported in tumour xenografts.
However, expression of cytokeratins did not concord regularly with that of the surface markers. In particular, expression of
CD90 and CK14 diverged during enrichment of CD90+ cells by immunomagnetic sorting or following cisplatin treatment.
Enriched CD90+ cells did not exhibit CSC-like characteristics like enhanced clonogenicity and cisplatin resistance.
Moreover, selection of cisplatin-resistant sublines by long-term drug treatment did not result in enrichment of CD90+
cells. Rather, these sublines displayed significant phenotypic plasticity expressing EMT markers, an altered pattern of CKs,
and WNT-pathway target genes.
Conclusions: Our findings indicate that the correspondence between CD surface markers and cytokeratins reported in
xenografts is not maintained in commonly used UCCs and that CD90 may not be a stable marker of CSC in
UC. Moreover, UCCs cells are capable of substantial phenotypic plasticity that may significantly contribute to
the emergence of cisplatin resistance.
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Background
Bladder cancer (BC) is the 9th most common tumour
world-wide and the most common cancer of the urinary
tract [1]. In developed countries, about 90 % of BCs are
urothelial carcinomas (UC) which may be further di-
vided into two subgroups, as muscle-invasive and non-
muscle-invasive. UCs are distinct in clinical behaviour
and molecular alterations [2]. Muscle-invasive tumours,
comprising up to one third of UC, frequently progress
to metastatic disease and face a poor prognosis with only
50–60 % survival after 5 years [3]. In advanced and/or
metastatic UC, platinum-based combination chemother-
apy is the standard first-line treatment in the periopera-
tive and the palliative setting [4, 5]. However, its impact
on cancer-specific survival is limited. Despite frequent
initial treatment responses, overall survival does not ex-
ceed 12–16 months in metastatic patients [6].
Resistance to cisplatin in UC is brought about by a var-
iety of mechanisms [7]. In particular, resistance may
emerge via repopulation by cancer stem cells (CSC) [8, 9].
According to this model, while significantly reducing can-
cer cell burden, cisplatin treatment indirectly stimulates
CSC to promote cancer recurrence. Hence, targeting these
cells would increase the efficacy of platinum-based
chemotherapy. However, it is contentious how to define
CSC populations in UC and they could differ between in-
dividual cases [10, 11]. Generally, CSCs are thought to
possess self-renewal potential, to reversibly enter quies-
cent or dormant states, and to be more resistant to cyto-
toxic drugs, thereby contributing to therapeutic resistance
[9, 12–14]. To which extent these properties apply to CSC
in UC is unknown.
In addition to CSC, urothelial tissue hierarchy and the
mechanisms regulating its normal or aberrant differenti-
ation are incompletely understood. Previously, all cell
types of the normal urothelium were thought to origin-
ate from the least differentiated basal cells, positive for
both cytokeratin 5 (CK5) and cluster-of-differentiation-
44 (CD44) [15, 16]. CK14 is a further marker for basal
cells which is rarely detectable in normal urothelium,
but significantly expressed in cells with squamous differ-
entiation [17]. Intermediate cells and terminally differen-
tiated umbrella cells expressing uroplakins and CK20
were thought to develop from basal cells. However, new
data argues for a second urothelial lineage producing
intermediate and umbrella cells [18, 19]. Thus, the cells
of origin of UC remain unidentified. Numerous attempts
to isolate CSCs from UC tumour tissues have yielded
heterogeneous marker profiles [20–22].
In studies aiming at defining molecular subtypes of
UC, de novo expression of CK14 in a so-called ‘basal’
subtype was generally indicative of unfavourable progno-
sis [10, 20, 22], suggesting that a subpopulation of less
differentiated, CK14-positive cells might drive an
aggressive type of UC. Further, in silico analysis of ex-
pression data and xenograft experiments using primary
patient-derived cells led has to a hierarchical ‘differenti-
ation state’ model for UC [10]. In this model, cellular
subpopulations within primary UC tumours were
assigned to ‘differentiation states’ according to a corre-
lated expression profile of cytokeratins (CK14, CK5,
CK20) and surface markers (CD90, CD44, CD49f)
(Fig. 1a). CD90 and CK14 double positive cells were the
least differentiated cell type in primary UC specimens
and were highly tumourigenic in xenograft experiments,
implicating CD90 and CK14 as markers of a CSC popu-
lation in UC. Of note, the abundance of subpopulations
was also heterogeneous in primary tumours and CD90-
positive cells could not be isolated from every patient. In
such cases, the next least differentiated subpopulation in
the postulated hierarchy proved to be tumourigenic in
xenografts. Unfortunately, such cell populations were
not further phenotypically characterized regarding stem-
ness or cisplatin resistance due to limited material from
primary tissues. Thus, we wondered whether this model
also holds for established UC cell lines (UCCs), which
are commonly used as models of the disease [23] and
allow detailed characterization of cellular properties and
differentiation hierarchies.
To this end, we determined the abundance of CK14/
CD90-positive cells in UCCs and investigated whether
they possess stem cell-like properties and are more re-
sistant against treatment with cisplatin. In detail, we de-
termined expression levels and distribution of CD90,
CD44, and CD49f as well as CK14, CK5, and CK20 in a
panel of 11 UCCs representing various subtypes, stages,
and grades of the disease. Further, we examined the cor-
relation between CD90 and CK14 expression and ana-
lysed clonogenic and proliferative potential as well as
cisplatin sensitivity of CD90+ cells after immunomag-
netic enrichment and flow cytometry-based sorting. In
addition, we evaluated whether short-term or long-term
treatment with cisplatin enriched for CD90-positive
cells.
Methods
Cell culture, treatment, and transfection
The human UC cell lines RT-112, VM-CUB-1, UM-UC-3,
T24, 639 V, 253 J, 5637, SW170, HT-1376, BFTC-905, and
J82, kindly provided by M. A. Knowles (Leeds, UK), J. Fogh
(New York, NY), B. Grossmann (Houston, TX), or the
DSMZ (Braunschweig, Germany), were grown in DMEM
GlutaMAX-I (Gibco, Darmstadt, Germany) containing
10 % fetal calf serum. All cell lines were recently verified by
standard DNA fingerprint analysis. For short-term experi-
ments a single dose of cis-diamminedichloroplatinum-II
(cisplatin; Accord Healthcare, London, UK) was added for
72 h; long-term treated (LTT) UCCs were generated by
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adding cisplatin after every passage at escalating doses
over 8–10 months. Niclosamide was purchased from
Sigma-Aldrich (#N3510, St. Louis, MO) and dissolved in
DMSO. Reporter plasmids TopFlash or FopFlash (Merck
Millipore, Billerica, MA) and mutated β-catenin-S33Y,
kindly provided by H. Clevers (Utrecht, The Netherlands),
were transfected using X-tremeGENE9 DNA Transfection
Reagent (Roche, Basel, Switzerland) according to the man-
ufacturer’s instructions.
RNA extraction, cDNA synthesis, and quantitative real-time
PCR
RNA was prepared using QIAzol Lysis Reagent (Qiagen,
Hilden, Germany) and RNeasy Mini Kit (Qiagen, Hilden,
Germany) according to the manufacturer′s instructions.
cDNA-synthesis was performed using the QuantiTect Re-
verse Transcription Kit (Qiagen, Hilden, Germany). Quan-
tiTect SYBR Green (Qiagen, Hilden, Germany) was used
for quantitative real-time PCR. Gene expression levels
were determined using self-designed primers on the Light-
cycler 2.0 Instrument (Roche, Basel, Switzerland)
(Additional file 1: Table S1). The housekeeping gene TBP
was routinely used for normalization of marker gene ex-
pression results. As TBP levels appeared to be slightly af-
fected by treatment with cisplatin, we used the
housekeeping gene SDHA for normalizing data of some
experiments.
Measurement of cell viability and proliferation
Cell viability was generally measured in quadruplicates
by means of MTT assay (Sigma-Aldrich, St. Louis, MO).
For the reason of increased sensitivity the CellTiter-Glo-
assay (Promega, Fitchburg, WI) was used to analyse rare
cells from FACS sorting experiments.
Immunofluorescence
UCCs were fixed on coverslips with 4 % formaldehyde.
Cells were permeabilized at room temperature for
10 min with ice-cold methanol, 30 min with 0.1 % sap-
onin, and 3 min with 0.5 % Triton-X-100 for E-cadherin,
Vimentin, and β-catenin staining, respectively. Subse-
quent to blocking, UCCs were incubated with primary
Fig. 1 UCCs are heterogeneous for cytokeratin expression and proportions of differentiation states. a Differentiation state model of UC according to
Volkmer et al. [10]. Relative mRNA expression of epithelial markers E-cadherin and miR-200 and mesenchymal markers Vimentin and ZEB1 (b) and CK14,
CK5, and CK20 (c) measured by qRT-PCR in a panel of 11 human UCCs. UCC expression levels were quantified relative to an internal standard. TBP was
used as reference gene. d Mean percentages of CD90, CD44, and CD49f positive cells in 11 UCCs as measured by flow cytometry. UCCs were categorized
into epithelial and mesenchymal phenotype. Values are expressed as the mean ± SD of triplicates
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antibodies (E-cadherin #3195, Cell Signaling, Cambridge,
UK, 1:100; CD90 ab133350, Abcam, Cambridge, UK,
1:200; CK14, Clone CKB1, Sigma-Aldrich, St. Louis,
MO, 1:50; Vimentin, ab92547, Abcam, Cambridge, UK,
1:400; β-catenin, #9562, Cell Signaling, Cambridge, UK,
1:50). Secondary antibodies (Life Technologies, Carlsbad,
CA) were added for 1 h in the dark at room-
temperature. Cover slips were counter-stained with
0.5 mg/ml DAPI.
Clonogenicity and sphere formation assay
CD90+ and CD90− cells were seeded after magnetic or
FACS sorting into 6 cm plates at a density of 3 × 103
cells per well. Visible clones were consecutively fixed in
50 and 100 % methanol before Giemsa staining (Merck,
Darmstadt, Germany). Sphere formation was analysed
subsequent to FACS sorting and automated deposition
of single cells.
Cell separation
For CD90 separation, 15 × 106 cells were labelled with
CD90-PE antibody and captured by means of anti-PE
microbeads and a magnetic LS-column according to
the manufacturer’s protocol (Miltenyi Biotec GmbH,
Bergisch Gladbach, Germany). FACS sorting was per-
formed by a MoFlo XDP with Summit 5.3 software
(Beckman Coulter, Brea, CA).
Flow cytometry
Expression of cell surface markers CD90, CD44, and CD49f
was determined using a MACSQuant flow cytometer using
the MACSQuant Analyzer 10 software (Miltenyi Biotec
GmbH, Bergisch Gladbach, Germany) and labelled anti-
bodies CD90-PE, CD44-APC, and CD49f-FITC (Miltenyi
Biotec GmbH, Bergisch Gladbach, Germany).
Statistical analysis
Statistical analysis was performed with SPSS Statistics
software version 21 (IBM, Armonk, NY). Differences be-
tween groups were analysed using Student’s t-test after
checking for normal distribution of results. All differences
highlighted by asterisks were statistically significant and
are encoded in figures as P <0.05 * or P <0.001 **.
Results
UCCs are heterogeneous for cytokeratin expression and
proportions of differentiation states
First, we characterized a representative panel of 11
UCCs for the expression of markers associated with cel-
lular morphology (mesenchymal-like vs. epithelial-like),
cytokeratins (CKs) CK14, CK5, and CK20 and cluster-
of-differentiation (CD) surface markers CD90, CD44,
and CD49f. According to the recently published hier-
archical ‘differentiation state model’ for UC the
correlated expression of both CK and CD markers may
be used to assign cellular subpopulations to three de-
fined differentiation states (Fig. 1a) [10]. Differences in
morphology among UCCs were also reflected distinct-
ively on the molecular level. As expected, epithelial
markers (E-cadherin, miR200) were almost exclusively
expressed in cell lines with epithelial morphology (VM-
CUB-1, BFTC-905, HT-1376, RT-112, 5637). In contrast,
mesenchymal markers (Vimentin, ZEB1) were almost
undetectable in UCCs with an epithelial phenotype, but
strongly expressed in UCCs with a mesenchymal pheno-
type (253 J, 639 V, T24, UM-UC-3, SW-1710, J82;
Fig. 1b). Surprisingly, expression analysis of cytokeratins
revealed that mesenchymal phenotype UCCs lacked
RNA-expression of CK14, CK5, and CK20 (Fig. 1c). In
addition, cytokeratin expression differed also among epi-
thelial UCCs. Whereas the CK14 expression level in
VM-CUB-1 cells resembled that of normal cultured
uroepithelial cells from ureters (data not shown), expres-
sion was 14-fold higher in HT-1376 cells and 5-fold
lower in RT-112. CK5 was robustly expressed in all
epithelial-like UCCs, with the exception of HT-1376,
and CK20 was detectable in BFTC-905, HT-1376, and
RT-112.
As expected, we observed a heterogeneous distribution
of the cell surface markers CD90, CD44, and CD49f by
flow cytometry among UCCs. In contrast to cytokeratins,
surface markers were generally expressed independently
of the morphological phenotype (Fig. 1d, Additional file 2:
Figure S2). In many UCCs only a small number of cells
were positive for CD90, whereas other lines contained sig-
nificant numbers of CD90-positive cells, so that their
abundance varied between 0.75 and 99.5 % across the
panel. For example, the 639 V cell line appeared to contain
exclusively triple-positive (i.e. CD90+ CD44+ CD49f+)
cells. Intriguingly, this cell line did not express CK14 at
detectable levels. With the exception of HT-1376, all
cell lines contained a high fraction of CD44+ cells.
Similarly, almost all UCCs were CD49f+, only the cell
lines SW-1710 and J82 contained few CD49f+ cells
(Fig. 1d, Additional file 2: Figure S2). Taken together,
this characterization demonstrated that UCCs collect-
ively reflect the heterogeneity observed among pri-
mary UCs, but also indicated that the proposed
correlation between CK and CD markers does not
apply to UCCs, especially in mesenchymal cell lines
lacking cytokeratins.
Enrichment of CD90+ cells does not enrich for CK14
expression in UCCs
We further investigated the postulated correlation be-
tween CD90 and CK14 by enrichment of CD90-positive
cells and subsequent expression analysis of cytokeratins.
To this end, we selected three cell lines representative
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for different epithelial-like or mesenchymal-like pheno-
types, with variable expression of CD90 and CK14 (RT-
112: epithelial, CD90low, CK14intermediate; J82: mesenchy-
mal, CD90low, CK14low; HT-1376: epithelial, CD90low,
CK14high). The efficiency of immunomagnetic enrich-
ment of CD90+ cells was monitored by triple staining
(CD90, CD44, CD49f) via flow cytometry. After enrich-
ment the abundance of CD90-positive cells was signifi-
cantly increased up to 50 % (Fig. 3a, Additional file 3:
Figure S1a). Subsequently, mRNA expression of CK14,
CK5, and CK7, which is known to be robustly expressed
in all uroepithelial cells, was quantified by qRT-PCR
(Fig. 2a). As expected, the pan-urothelial cytokeratin
CK7 did not differ significantly between the populations.
However, CK14 expression, too, was not significantly dif-
ferentially expressed between CD90+ and CD90− cell
fractions. CK5, a marker of basal and intermediate dif-
ferentiation states in UC (Fig. 2a), was invariable in RT-
112, but decreased in the CD90− fraction of HT-1376.
Concurring with the analysis above (Fig. 1c), CK5 ex-
pression was below the limit of detection in J82 cells
(Fig. 2a). Accordingly, immunofluorescence staining for
CD90 and CK14 demonstrated that both markers were
heterogeneously expressed in the cell lines, but not gen-
erally co-expressed, as illustrated for the HT-1376 cell
line in Fig. 2b.
CD90+ UCCs do not exhibit a distinct stem cell-like
phenotype
Next, we investigated whether CD90+ cells isolated from
UCCs exhibit CSC properties by measuring clonogeni-
city, self-renewal and differentiation capacity or in-
creased resistance to cisplatin. Following magnetically
CD90 enrichment or depletion, CD90+ and CD90− sub-
populations of RT-112, J82 and, HT-1376 were recul-
tured and followed over time. After reculturing, the
number of CD90+ cells in enriched cultures regressed to
baseline expression. Interestingly, in the CD90 depleted
subpopulation, the amount of CD90+ cells likewise in-
creased to the baseline level (Fig. 3a, Additional file 3:
Figure S1b). Similarly, we did not observe any difference
in colony forming potential between CD90 enriched and
CD90 depleted cell fractions subsequent to immuno-
magnetic sorting (Fig. 3b; MACS panel). Since immuno-
magnetic sorting only allows enrichment but not
complete separation of cell fractions, RT-112 and HT-
1376 cell lines were additionally sorted by flow cytometry.
Colony formation assays of highly purified cell fractions
revealed a slight advantage for CD90+ cells (Fig. 3b; FACS
panel). We also analysed self-renewal capacity subsequent
to FACS sorting by seeding single cells in 96-well-plates.
Although spheres from CD90+ cells appeared to grow
slightly faster (Fig. 3b; right panel) we did not observe a
significant difference in the number of colonies originating
from single CD90+ or CD90− RT-112 cells. Thus, RT-112
CD90− cells as well exhibited self-renewal capacity. HT-
1376 cells did not form colonies after single cell isolation
(data not shown).
Additionally, CD90+ magnetically enriched and FACS
sorted cell fractions were examined for their cisplatin sen-
sitivity. CD90+ enriched cell fractions from RT-112, J82,
and HT-1376 cell lines were no more resistant to cisplatin
than the corresponding CD90 depleted fractions (Fig. 3c).
However, highly purified FACS sorted CD90+ cells were
less sensitive to cisplatin treatment than CD90− cells from
RT-112 and J82 cell lines (Fig. 3d).
UCCs sensitivity towards short-term treatment with cisplatin
is not correlated with abundance of CD90+ cells
To investigate the relation between the abundance of
CD90+ cells and cisplatin sensitivity, we sought to iden-
tify the appropriate doses and time schedule for cisplatin
treatment. Thus, we determined IC50 concentrations for
cisplatin after 48 and 72 h and also checked for changes
Fig. 2 Enrichment of CD90+ cells does not enrich for CK14 expression in UCCs. a Relative RNA expression of CK7, CK14, and CK5 in RT-112, J82,
and HT-1376 cells magnetically enriched for CD90. Expression levels of the CD90+ cell fraction were set as 1. nd not detectable. b Representative
immunofluorescence stainings of CD90 (red) and CK14 (green) for cell lines RT-112, J82, and HT-1376; DAPI was used for nuclear staining. Scale bars, 50 μm.
Values are expressed as the mean ± SD of triplicates
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Fig. 3 (See legend on next page.)
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in the abundance of CD90+ cells from 24 to 96 h by flow
cytometry (Fig. 4a). Based on the results, the following
experiments were performed within a period of 72 h,
IC50 values ranged between 1.07 and 12.5 μM (Fig. 4a).
Across the cell lines, no correlation was obvious between
the abundance of CD90+ cells (Fig. 1d) and sensitivity to
cisplatin (Fig. 4a). For instance, the 639 V cell line com-
prising the biggest fraction of CD90+ cells was highly
sensitive to cisplatin, whereas RT-112 containing a small
fraction of CD90+ cells was the most resistant cell line.
However, following short-term treatment (STT) with cis-
platin at IC50 doses for 72 h, the abundance of CD90
+
cells increased significantly in 6/11 UCCs, particularly in
cell lines with originally low abundance of CD90+ cells
(Fig. 4b, Additional file 2: Figure S2). The fraction of
CD44+ and CD49f+ cells was augmented only in UCCs
with low abundance of these markers, namely HT-1376
(CD44low) and J82 (CD49flow).
We additionally analysed the cell lines with an in-
creased fraction of CD90+ cells after cisplatin treatment
(See figure on previous page.)
Fig. 3 CD90+ UCCs do not exhibit a distinct stem cell-like phenotype. a CD90+ fraction in unsorted (grey bars), CD90 enriched (dark grey bars), CD90
enriched cells after reculturing for about 7–8 population doublings (dark grey bars, shaded), CD90 depleted (white bars), and CD90 depleted cells after
reculturing (white bars, shaded) in RT-112, J82, and HT-1376 as measured by flow cytometry. b Clonogenic potential in magnetically and FACS sorted
CD90+ and CD90− populations from RT-112, J82, and HT-1376 cell lines shown by Giemsa staining. Colony-forming potential of single cells positive or
negative for CD90 from RT-112 cells after FACS sorting. Phase-contrast microscopy, scale bars, 100 μm. c Cisplatin sensitivity was measured in unsorted
and MACS sorted CD90+ and CD90− fractions of RT-112, J82, and HT-1376 by MTT assay after 72 h treatment. Untreated cells were set as 100. d Relative
cisplatin sensitivity of FACS sorted CD90+ and CD90− cells from RT-112 and HT-1376 cell lines as measured by CellTiter-Glo Luminescent Cell Viability Assay
after 72 h cisplatin treatment with IC50 concentrations (see Fig. 4a). Untreated cells were set as 1. Values represent the mean± SD of quadruplicates. *P <0.05;
**P <0.001
Fig. 4 UCCs sensitivity towards short-term treatment with cisplatin is not correlated with abundance of CD90+ cells. a Cell viability was measured
72 h after cisplatin treatment by MTT assay in 11 UCCs, categorized into UCCs with epithelial (dark grey bars) and mesenchymal (light grey bars)
phenotypes. b Subsequent to short-term treatment with cisplatin (STT, 72 h) most cell lines displayed increased numbers of CD90+ cells. Mean
percentages of CD90+ cells in untreated (dark grey bars) and STT (dark grey bars, shades), CD44+ cells in untreated (light grey bars) and STT (light
grey bars, shades), and CD49f+ cells in untreated (grey bars) and STT (grey bars, shades) UCCs as measured by flow cytometry. c) Relative expression
of CK14, CK5, and CK20 was measured by qRT-PCR in a panel of 11 untreated and STT-UCCs. Expression in the respective untreated control cells
was set as 1. Data represent the mean ± SD of three independent experiments. SDHA was used as reference gene and relative expression calculated
by using the 2−ΔΔCT method. Untr Ctrl untreated control, STT short-term cisplatin treatment. *P <0.05; **P <0.001
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for cytokeratin RNA expression. Again, cytokeratins gen-
erally expressed in uroepithelial cells, like CK7 and
CK13, remained mostly unchanged and no increase in
CK14 expression was observed (Fig. 4c).
Long-term cisplatin treated UCCs are not enriched for
CD90+/CK14+ cells
Since some enrichment of CD90+ cells was observed
after short-term treatment with cisplatin, we wondered
whether long-term cisplatin treatment further selects for
this cell fraction. RT-112, J82, and HT-1376 cells under-
went long-term cisplatin treatment (LTT) over several
months with escalating doses, following a protocol simi-
lar to the Resistant Cancer Cell Line (RCCL) collection
[24]. Ultimately, resistant RT-112 and J82 cells could be
maintained as proliferating cultures with 50 and 1.6 μM
cisplatin, respectively, added after each passage. No
long-term surviving cells could be obtained from HT-
1376. IC50, determined after 72 h treatment of LTT cell
lines, increased significantly compared to the
corresponding parental cells. In RT-112-LTT IC50 for
cisplatin was >50 μM compared to 12.5 ± 2.7 μM in the
parental cells and IC50 for J82-LTT increased from 1.5 ±
0.48 μM to 9.2 ± 4.2 μM. The RT-112-LTT cells grew
much slower than the parental line, with population
doubling times of 32.7 and 25.3 h, respectively. Similar
results were found in J82-LTT and untreated parental
J82 with doubling times of 33.1 and 24.5 h, respectively
(Fig. 5a). Moreover, the LTT-UCCs were much less clo-
nogenic than the parental cells in the absence of cis-
platin (Fig. 5b). However, upon cisplatin treatment, only
LTT-UCCs were capable of clonogenic growth compared
to the parental controls indicating their growth advan-
tage through acquired cisplatin resistance (Fig. 5b). Sub-
sequently, CD90-, CD44- and, CD49f-positive cell
fractions as well as mRNA expression of CK7, CK13,
and CK14 were determined in theRT-112-LTT and J82-
LTT. In contrast to the STT, CD90+ cells were not
enriched in LTT sublines (Fig. 5c, Additional file 4:
Figure S3). The fraction of CD44 and CD49 positive cells
Fig. 5 Long-term cisplatin treated UCCs are not enriched for CD90+/CK14+ cells. a Relative cell number in RT-112-LTT and J82-LTT and parental
cell lines was measured by MTT after 24, 48, 72 and 96 h. Population doubling time was calculated based on raw absorbance data. b Clonogenic
potential of RT-112-LTT and J82-LTT and parental cell lines without or with cisplatin, Giemsa staining. c Mean percentages of CD90+ cells in untreated
(dark grey bars) and LTT (dark grey bars, shades), CD44+ cells in untreated (light grey bars) and LTT (light grey bars, shaded), and CD49f+ cells in untreated
(grey bars) and LTT (grey bars, shaded) UCCs as measured by flow cytometry. d Relative expression of CK7, CK13, and CK14 in untreated and LTT-UCCs.
Expression levels in the untreated control were set as 1. SDHA was used as a reference gene and relative expression was calculated by the 2−ΔΔCT method.
Values represent the mean ± SD of biological triplicates. Untr Ctrl untreated control, LTT long-term cisplatin treatment, PDT population
doubling time, na not available. *P <0.05; **P <0.001
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also remained largely unchanged as compared to the
parental cell lines. To corroborate our results on resist-
ant RT-112 and J82 cells, further resistant UCCs were gen-
erated (Fig. 5c, Additional file 4: Figure S3; VM-CUB-1-
LTT, 5637-LTT, 253 J-LTT, T24-LTT, SW-1710-LTT). In
these cell lines, too, CD90+ cells were not enriched com-
pared to their parental UCC. On the contrary, a significant
decrease of CD90+ cells was observed in 5637-LTT and
T24-LTT. Expression of CK14 was not increased in any
LTT-cell line, rather expression of cytokeratins decreased
generally (Fig. 5d). Fitting the decreased expression of cyto-
keratins, RT-112-LTT and J82-LTT cells underwent mor-
phological changes. While parental RT-112 cells form
epithelial colonies with strong cell-to-cell-adhesion, RT-
112-LTT colonies were less compact and cells often as-
sumed a more mesenchymal phenotype (Fig. 6a). Com-
pared to the untreated controls, RT-112-LTT and J82-LTT
increased in size. In summary, morphological changes
pointed towards an epithelial to mesenchymal transition
(EMT) in UCCs upon LTT.
Phenotypic plasticity of UCCs facilitates evasion from
long-term treatment with cisplatin
To verify that UCCs undergo EMT upon long-term
treatment with cisplatin, we compared the mRNA levels
of E-cadherin, Vimentin, ZEB1, and Twist1 between pa-
ternal and LTT-cells (Fig. 6b). In accord with the mor-
phological changes, expression of the epithelial marker
E-cadherin decreased significantly in RT-112-LTT and
J82-LTT whereas expression of the mesenchymal marker
Vimentin increased significantly. Likewise, the expres-
sion of transcription factors inducing EMT, such as
ZEB1 and Twist1, was increased in the LTT-lines, albeit
not significantly in RT-112-LTT. As we observed less
tight cell-cell-contacts after cisplatin treatment, we also
quantified the expression of CLDN3 and CLDN4, encod-
ing structural molecules of tight junctions. Indeed,
CLDN3 and CLDN4 expression was decreased in RT-
112-LTT (Fig. 6c), derived from an epithelial cell line,
but not in in J82-LTT, derived from a cell line with mes-
enchymal phenotype. IF staining for E-cadherin in RT-
112-LTT and Vimentin in J82-LTT confirmed the mRNA
results (Fig. 6b, d). Further, IF staining for β-catenin re-
vealed diminished membrane localisation, but no major
shift into the nucleus (Fig. 6e).
Activation of WNT-signalling may contribute to survival
of UCCs upon long-term cisplatin treatment
As some results pointed towards an activation of ca-
nonical WNT-signalling in LTT-cells, we measured
downstream targets of the pathway, namely AXIN-2,
CCDN1, c-MYC, and PITX2. Indeed, the mRNA ex-
pression of these genes was increased in LTT-UCCs
compared to their parental cell lines (Fig. 6f ). We fur-
ther confirmed augmented WNT-pathway activity by
the TOP-FOPflash-assay indicating that the pathway
could be activated by transfection of mutant β-
catenin-S33Y in RT-112-LTT, but not in parental cells
(Fig. 6g) [25]. Positive controls for endogenous and
inducible β-catenin activity in HepG2 and 22Rv1 cell
lines, respectively, demonstrated the functionality of
the assay (Fig. 6g). Next, we investigated whether
treatment of LTT sublines with the WNT-inhibitor
niclosamide might revert cisplatin resistance of the
cells. To this end we performed a dose response
curve for niclosamide after 72 h treatment (Additional
file 5: Figure S4a). We used the colorectal carcinoma
cell line HCT-116 as a control for a cell line with sig-
nificant WNT-pathway activity [26]. HCT-116 cells
were more sensitive towards niclosamide treatment than
RT-112-LTT and J82-LTT, as well as their parental cell
lines (Additional file 5: Figure S4a, b). As expected, treat-
ment of HCT-116 cells with niclosamide for 72 h at IC50
resulted in downregulation of the WNT/β-catenin targets
β-catenin, Axin-2, and CyclinD1 (Additional file 5:
Figure S4c upper panel; p <0.05). We further demon-
strated that WNT-signalling activity could be signifi-
cantly inhibited in HCT-116 cells by the applied doses
of the compound in the TOP-FOPflash-reporter assay
(Additional file 5: Figure S4d). Thus, the compound is
active at the applied concentrations in cell lines with
canonical activation of the WNT/β-catenin signalling.
However, we did not observe synergistic effects on cell
viability of resistant LTT cell lines by combined treat-
ment with cisplatin and niclosamide (Fig. 6h) indicating
that cisplatin resistance could not be reverted by this
inhibitor. Moreover, treatment with niclosamide did
not result in significant expression changes of WNT-
target genes UC cells (Additional file 5: Figure S4c,
lower panel).
Discussion
Since drug resistance remains a major limitation to UC
chemotherapy [9], a better understanding of mechanisms
underlying both, inherent or acquired resistance, appears
mandatory to overcome the current stagnation in thera-
peutic efficiency. Inherent drug resistance may originate
from CSC endowed with self-renewal capacity and inher-
ent chemoresistance [27, 28]. However, the identity of
CSC in UC has not been clearly defined. Accordingly, a
better understanding of the cell lineages in benign and
cancerous urothelial tissues is urgently needed. Likewise,
the identification of specific markers for isolation of indi-
vidual cell populations will be a prerequisite for a compre-
hensive characterization of their cellular properties.
In the past, a variety of markers, which had mainly
been developed from studies of normal adult stem cells
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Fig. 6 (See legend on next page.)
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[29], have been used to identify CSC in solid tumours,
leading to heterogeneous or sometimes contradictory re-
sults [30]. The issue is complicated by tumour hetero-
geneity and by the possibility that tumours might
contain more than one distinct CSC population [31]. Pu-
tative CSCs have been isolated from many tumour types
including leukaemia, melanoma, and various carcinomas
using markers such as CD133, CD24, CD44, and
ALDH1 [32, 33]. Obviously, markers suitable for one
cancer type may not be universally applicable. For ex-
ample, CD24 is frequently used to isolate CSCs from
solid tumours, e.g. breast cancer, but does not enrich
tumour-initiating cells from UC [34]. Instead, CD90+
and CK14+ have been recently postulated as markers for
CSC in UC identifying cells in a basal, less differentiated
state [10]. Expression of both markers in this subpopula-
tion was positively correlated. CD90+ cells isolated from
primary UC were highly tumourigenic in xenograft ex-
periments [10]. Notably, attempts to develop signatures
for molecular subtypes of UC [8, 19] revealed an associ-
ation between CK14 expression and squamous differen-
tiation as well as with poor prognosis. Volkmer et al.
[10] further proposed a model of differentiation states in
UC characterized by co-expression of surface markers
and cytokeratins (Fig. 1a). As characterization of cellular
subpopulations isolated from primary tumours is ham-
pered by limited material and tumour heterogeneity, we
decided to investigate whether the postulated markers
and relationships could be detected in established UCCs
and be used to isolate subpopulations. Our results show
that the proposed model does not hold in its entirety for
the UCC lines that are commonly used as models of the
disease.
Initially, we generated an expression profile for
markers of cellular morphology, cytokeratins and CD
surface markers in a representative panel of 11 UCCs. The
expression of EMT marker genes correlated with the
morphologic appearance of the cell lines, allowing a
categorization of the cell lines into either epithelial or
mesenchymal phenotypes. Importantly, UCCs with a mes-
enchymal phenotype did not express CK14, CK5, or CK20
at detectable levels. In UCCs with an epithelial phenotype,
expression of the cytokeratins was heterogeneous in keep-
ing with the heterogeneity observed for primary tissues
and xenografts [10]. Generally, CK14 expression was ra-
ther restricted, as expected for a marker of CSC, which
are thought to constitute a minority among the tumour
cells. FACS analysis for the surface markers CD90, CD44,
and CD49f also revealed heterogeneity within and among
the UCCs. Again, as expected for a putative CSC marker,
CD90+ cells were rather rare in most cell lines, but were
more frequent in some mesenchymal-like cell lines, even
though they did not express CK14. As, in contrast to cyto-
keratins, CD markers were well detectable, neither the
postulated correlation between CD90 and CK14 expres-
sion, nor the correlation between other surface markers
and other cytokeratins exist in mesenchymal phenotype
UCCs. Moreover, we did not observe any increase in
CK14 expression following enrichment of CD90+ cells by
sorting or by short-term cisplatin treatment, even in cells
with an epithelial phenotype. Immunofluorescence stain-
ings for CD90 and CK14 likewise revealed divergences be-
tween the two markers. These observations obviously
raise the question of whether UCC have lost the co-
expression of CD90 and CK14 during cultivation or
whether the association between the markers observed in
vivo is only a statistical correlation. In particular, the cell
type corresponding to the UCCs with a mesenchymal
phenotype in vivo remains to be identified. In this respect,
changes in cellular morphology towards EMT occur at the
invasive tumour front [35], but the mesenchymal pheno-
type in vitro is stable over many passages [36].
As almost all cells of UCCs and of normal uroepithe-
lial cell cultures appeared broadly positive for CD44 and
CD49f, these proteins are unlikely candidates for CSC
markers in UC. Urothelial CSCs are likely to be positive
for CD44, but further specific markers would be needed
for their isolation. Chan et al. [37] reported that 13 out
of 14 primary UC were positive for CD44 to various ex-
tents and that the CD44+ subpopulation displayed in-
creased tumour-initiating capacity in xenografts, but
CSCs could not be purified by means of CD44 only.
Moreover, CD44 is broadly expressed in the normal
urothelium, UC, and even in stromal cells [34], barring
its application as a marker on its own for the isolation of
UC CSC [38].
To investigate whether CD90 is a reliable marker of
CSC in UCCs, we further characterized cellular
(See figure on previous page.)
Fig. 6 Activation of WNT-signalling may contribute to survival of UCCs upon long-term cisplatin treatment. a Morphology of RT-112-LTT and J82-
LTT and their parental cell lines. Scale bars, 100 μm. qRT-PCR demonstrated relative expression levels of E-Cadherin, Vimentin, Twist1, ZEB1 (b) and
CLDN3 and CLDN4 (c) in RT-112-LTT and J82-LTT and their parental cell lines. d Immunofluorescence stainings for E-cadherin and Vimentin (d) and
β-Catenin (e) in RT-112-LTT and J82-LTT and their parental cell lines. DAPI staining (blue) was used to visualize nuclei. Scale bars, 50 μm. f Relative
RNA expression levels of β-Catenin, AXIN-2, CCDN1, c-MYC, and PITX2 in untreated and RT-112-LTT and J82-LTT. Expression levels in the untreated
control were set as 1. g Basal and inducible activity of a TCF/β-Catenin-dependent promotor. Mean ± SD of duplicates of TopFlash/FopFlash and
TopFlash+S33Y/TopFlash ratio are shown in RT-112-LTT and J82-LTT and their parental cell lines. 22RV1 and HepG2 cell lines were used as
controls. h Relative cell viability was measured 72 h after treatment with cisplatin, niclosamide, or combination of both by MTT assay in
RT-112-LTT and J82-LTT. *P <0.05; **P <0.001
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properties of the subpopulations in the UCCs that were
positive for CD90. Initially, we used a magnetic immu-
noenrichment technique (MACS) to enrich or deplete
CD90+ cells from UCCs. Upon reculturing these cell
fractions, we found that both fractions reconstituted a
similar proportion of CD90+ and CD90− cells. This find-
ing suggests an active regulation of the distribution of
differentiation states in the UCCs, as expected in a tissue
hierarchy. Of note, the restoration of the CD90+ popula-
tion from the depleted fraction might originate from the
remaining CD90+ cells within the depleted fraction due
to the impurity of magnetically enriched subpopulations
rather than dedifferentiation of CD90− cells. Neverthe-
less, we did not observe a significant increase in clono-
genicity or cisplatin resistance of the MACS-enriched
CD90+ fraction. Moderately increased clonogenicity
and cisplatin resistance was detected in highly purified
CD90+ cell fractions from FACS sorting. Concurring
with these observations, the CD90+ fraction was signifi-
cantly enriched in about half of the UCCs by short-
term treatment with cisplatin at IC50 concentrations,
while the other surface markers remained largely
unchanged. These data suggest that CD90+ cells might
indeed be more resistant to cisplatin and more clono-
genic than other fractions in the UCCs, but that the dif-
ferences are more quantitative than qualitative. Indeed,
in cisplatin-resistant sublines generated by long-term
treatment, we observed no selection for CD90+ cells. In
conclusion, CD90 might not constitute a stable marker
for cells that persist during cisplatin-based chemother-
apy in UC patients and drive recurrence and progres-
sion of the disease. Similarly, CK14 neither seems a
useful marker in this setting, as cytokeratin expression
was rather lost in long-term treated cells which tended
towards a more mesenchymal morphology.
LTT-UCCs were established by continuous exposure
to increasing cisplatin concentration as we were inter-
ested in selection for highly resistant cells and to
characterize them rather regarding stem cell properties
than comprehensively for resistance mechanisms. Thus,
underlying mechanism of acquired resistance might dif-
fer from resistant cell lines established by intermittend
protocols. However, to our knowledge, to date no con-
clusive data has been published on resistance acquired
by different treatment protocols. Further, our observa-
tions were in accordance with cell culture models with
acquired resistance from the RCCL [24]. Like docetaxel-
resistant prostate cancer cell lines [39], they were slow-
cycling, but displayed increased clonogenic capability
after treatment with cisplatin compared to parental cells.
As observed in many other cancer lines developing re-
sistance to chemotherapeutic drugs, e.g. from head and
neck cancers [40], A549 lung cancer cells [41] and ovar-
ian cancer [42], LTT-UCCs appeared to evade cisplatin-
induced apoptosis by phenotypic plasticity towards an
EMT-like phenotype. We observed morphological
changes into spindle-shaped and mesenchymal-looking
phenotype and gene expression changes indicative of
EMT, including changes in pertinent transcription fac-
tors and tight-junction protein genes. The relation be-
tween EMT and chemoresistance has been extensively
discussed in the context of the hallmarks of cancer and
properties of CSC [43–45].
Like acquisition of EMT, activation of WNT-signalling
was previously observed in cisplatin resistant non-small
cell lung cancer and osteosarcoma cell lines [41, 46].
WNT-signalling regulates cell growth and differentiation
and the maintenance of epithelial stem cell compart-
ments in various tissues [47]. Uncontrolled WNT-
signalling can lead to constitutive renewal and aberrant
expansion of the stem cell or progenitor pool [48, 49].
While WNT-signalling is involved in urothelial regener-
ation acting on the basal compartment [50], in untreated
UCCs WNT-signalling is not generally constitutively ac-
tivated [25, 51] and its function in UC is generally unre-
solved. While analysing the changes in intercellular
adhesion in LTT-UCC, we discovered some changes in
β-catenin intracellular localisation and its increased
expression. Typical downstream targets of canonical
WNT-signalling like AXIN-2, CCDN1, c-MYC, and
PITX2 were induced, suggesting activation of this path-
way subsequent to long-term treatment of UCC with
cisplatin. However, a reporter assay for active WNT-
signalling revealed only moderate stimulation of activa-
tion and a WNT-signalling inhibitor did not revert
resistance [52]. We reported already previously that ca-
nonical WNT-signalling is not generally constitutively
activated in untreated UCCs [25]. Thus, our new results
suggest that enhanced expression of typical WNT-target
genes could be part of the development of cisplatin re-
sistance in UCC, which might not result from the ca-
nonical Wnt-signalling that can be inhibited by
niclosamide, but rather from a crosstalk between differ-
ent pathways.
Despite the canonical WNT-pathway, signalling via β-
catenin, WNT can also signal via secondary pathways, as
such as protein kinase A and C, calcium-dependent signal-
ling, JNK or Rho-like GTPases. WNT-5a can activate some
of those, while inhibiting the canonical WNT-signalling in
parallel [53]. Thus, activation of WNT-ligands in the
course of resistance development may lead to an upregula-
tion of WNT-target genes in a β-catenin-independent
manner. This would explain why we observed changes in
WNT-target gene expression in LTT cells, but neither dra-
matic changes in β-catenin expression nor in the reporter
assay. Further, niclosamide, a typical WNT-inhibitor, af-
fected target gene expression in HCT-116 control cells, as
expected, but not in UCCs. These results point to the
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concept that induced expression of WNT-target genes in
resistant UCCs might rather originate from a context-
dependent crosstalk between different pathways (e.g. WNT,
NOTCH, Hedgehog, TGF-β) than from canonical WNT-
signalling. Components of the WNT-pathway have been re-
ported to interact with NOTCH components. Likewise the
Hedgehog pathway can modulate WNT-signalling, and dif-
ferent components can be shared between WNT- and
TGF-β-signalling [54, 55]. This networking of various path-
ways can lead to an activation of the β-catenin/TCF4 tran-
scription machinery in a non-canonical and alternate
manner. As a conclusion, neither differential expression of
WNT-target genes in resistant cells nor resistance itself
may be reverted by treatment with a WNT-inhibitor only
and might rather demand a combined inhibitor treatment
strategy.
Conclusions
In conclusion, the postulated differentiation markers
CK14, CK5, and CK20 as well as CD90, CD44, and
CD49f were neither sufficient to define a CSC popula-
tion in UCCs nor to define UCCs with an increased
resistance to cisplatin treatment. In addition, cisplatin
did not enrich for a UC population defined by these
markers, but rather induced phenotypic plasticity likely
to be associated with EMT and enhanced the WNT-
signalling activity. Thus, in the future LTT-UCCs need
to be characterized by expression profiling regarding the
mechanisms of cisplatin resistance [56] and further
investigated for surface molecules that might serve as
appropriate selective markers for the isolation of resist-
ant cancer stem cells.
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Additional file 1: Table S1. Primer sequences for quantitative real-time-
PCR. Sequences of primers (5′-3′) used for quantitative real-time-PCR including
length of PCR product and annealing temperature. bp base pair; Fwd Forward;
Rev Reverse. (DOC 48 kb)
Additional file 2: Figure S2. Endogenous abundance of subpopulations
from differentiation states and subsequent to short-term cisplatin treatment.
Original flow cytometry data displaying abundance of CD90, CD44, and CD49f
positive cells in 11 UCCs corresponding to the summarized data in Fig. 1d.
Unstained cells were used to set gates for positively stained cells. Subsequent
to short-term treatment with cisplatin (STT, 72 h) most cell lines displayed
increased numbers of CD90+ cells as also illustrated in Fig. 4b; representative
results from biological triplicates. STT: Short-term cisplatin treatment.
(TIF 4559 kb)
Additional file 3: Figure S1. CD90+ UCCs do not exhibit a distinct
stem cell-like phenotype. Original flow cytometry data for abundance
of CD90+ cells corresponding to the summarized data in Fig. 3. a) CD90+
fraction in unsorted (top), CD90 magnetically enriched (middle, indicated by
arrow) and CD90 depleted (bottom) cell cultures. b) Following reculturing
for 7–8 population doublings the number of CD90+ cells was determined
again in the respective fractions. (TIF 6628 kb)
Additional file 4: Figure S3. Long-term cisplatin treated UCCs are not
enriched for CD90+/CK14+ cells. CD90+, CD44+, and CD49f+ cells in untreated
and LTT UCCs as measured by flow cytometry and collectively illustrated in
Fig. 5c; representative results from biological triplicates. Unstained cells were
used to set gates for positively stained cells. One measurement is shown for
each cell line as a representative of biological triplicates. Untr. Ctrl.: Untreated
Control; LTT: Long-term cisplatin treatment. (TIF 3017 kb)
Additional file 5: Figure S4. Activation of WNT-signalling may contribute
to survival of UCCs upon long-term cisplatin treatment. a) Cell viability was
measured 72 h after niclosamide treatment by MTT assay in order to
determine b) IC50 values for RT-112, RT-112-LTT, J82, J82-LTT. HCT-116
cells served as a control. c) Relative RNA expression levels of β-Catenin, AXIN-2,
CCDN1, c-MYC, and PITX2 in untreated and niclosamide treated (72 h IC50)
HCT-116 cells (upper panel) as well as RT-112 and J82 parental cells (lower
panel). Expression levels in the untreated control were set as 1. d) Basal activity
of a TCF/β-Catenin-dependent promotor after niclosamide treatment in HCT-
116 control cells. Mean ± SD of duplicates of TopFlash/FopFlash ratio in
niclosamide treated HCT-116 cells and their untreated controls (Untr. Ctrl.).
(TIF 1747 kb)
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